First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma | OncLive

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13, 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Jessica Hergert.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Hearn Jay Cho, MD, PhD, an associate professor of medicine of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai Hospital and the chief medical officer of the Multiple Myeloma Research Foundation, and Irene Ghobrial, MD, a professor of medicine at Harvard Medical School and director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, to discuss the launch of CureCloud, the first comprehensive study of its kind in multiple myeloma.

The study, which will launch on July 14, 2020, was designed to serve as an invaluable resource to scientists and doctors who are working to find treatments, improve the quality of life of their patients, and ultimately, develop cures for those living with multiple myeloma.

In our exclusive interview, Dr. Cho and Dr. Ghobrial discussed the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.


x